EGFR and non-small cell lung carcinoma: In the latest national comprehensive cancer network (NCCN) guidelines of non-small cell lung cancer, gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib are all category 1 recommended EGFR TKIs [25].